We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abaxis (ABAX) Q1 Earnings Miss Estimates, Sales Up Y/Y
Read MoreHide Full Article
Abaxis, Inc. – a global provider of point-of-care blood analyzers, reported its first-quarter fiscal 2017 earnings per share (EPS) of 30 cents, which missed the Zacks Consensus Estimate by 9.1%.
The quarter’s EPS also dropped by a penny from the year-ago comparable figure.
The downside in the bottom-line results can primarily be attributed to a double-digit increase in operating expenses, a result of management’s decision to increase investments in research and development (R&D) and international sales and marketing (S&M).
Total Revenue
In the fiscal first quarter, Abaxis delivered revenues of $57.7 million, reflecting an 8.7% year-over-year increase. The top line however missed the Zacks Consensus Estimate of $59 million.
Notably, the mid-single-digit growth witnessed in its medical market segment and the double-digit growth in veterinary market segment collectively drove the high-single digit growth in Abaxis’ overall revenue during the first quarter.
Foreign currency exchange rate fluctuations had almost negligible impact on Abaxis’ top line growth, as currencies reduced total revenue growth by only 0.3% in the quarter.
In the quarter, on a geographic-region basis, revenues from North America (accounting for 81.1% of total revenue) grew 11% to $46.8 million, while revenues from the international market (accounting for the rest) rose 1.3% to $10.9 million.
Abaxis operates under three main segments, namely Veterinary, Medical and Other. In the reported quarter, Veterinary sales comprised 82.7% of total sales; Medical sales contributed 15.8% while the remaining 1.5% was generated from Other.
Veterinary market revenues improved 10% year over year to $47.7 million, driven by a 6% growth in veterinary consumable revenues and 27% growth in veterinary instrument revenues. Revenues from medical market segment grew 5% year over year at $9.1 million, on account of 11% increase in medical rotor revenue while Piccolo instrument revenues dropped 19%. Revenues from the Other segment increased 6.2% to $0.87 million.
Abaxis also exhibited a strong consumable growth, up 7% year over year to $44.7 million, accounting for approximately 77.5% of the company’s total worldwide revenues in the quarter. Total Instruments sales, also, increased 5% to $11.1 million.
Operational Updates
Fiscal first-quarter gross profit rose 9% to $32 million. However, gross margin expanded only 10 basis points (bps) to 55.5%, affected by sales mix during the quarter.
R&D expenses increased 10.8% year over year to $5.2 million, while S&M expenses rose 11.7% to $11.8 million. General and administrative expenses also rose 21.5% to $4.2 million. Although the resultant operating income came in almost flat at $10.7 million for the quarter, operating margin declined 140 bps to 18.6% owing to higher operating expenses.
Financial Update
Abaxis exited fiscal first quarter with cash, cash equivalents and short and long-term investments of $153 million, up from $129.8 million in the prior quarter.
Meanwhile, Abaxis' management has approved a $30 million increase to its existing share repurchase program, making the total amount available for repurchase to $54 million at present.
Our Take
Abaxis’ first-quarter fiscal 2017 results disappointed us, with the company squarely missing the Zacks Consensus Estimate. However, on a year-over-year comparable basis a strong outcome was observed, with global sales improving across all Abaxis’ segments as well as in geographical bases. Moreover a specific rebound in Europe’s veterinary rotor units’ sales is encouraging as Abaxis had displayed a dreary performance in this space in the past two quarters.
Abaxis faced a challenging year over year comparison in the Asia Pacific region this quarter. But for the remaining quarters of fiscal 2017, management offered an improved outlook anticipating increased sales of veterinary rotors in the region. Besides, the strong cash position of Abaxis is evident from management’s decision to increase the share repurchase fund, which all the more buoys our optimism for this stock.
Zacks Rank
Abaxis currently holds a Zacks Rank #3 (Hold). Some better-ranked medical stocks are Boston Scientific Corp. (BSX - Free Report) , NuVasive, Inc. and Lonza Group Ltd (LZAGY - Free Report) . All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Abaxis (ABAX) Q1 Earnings Miss Estimates, Sales Up Y/Y
Abaxis, Inc. – a global provider of point-of-care blood analyzers, reported its first-quarter fiscal 2017 earnings per share (EPS) of 30 cents, which missed the Zacks Consensus Estimate by 9.1%.
The quarter’s EPS also dropped by a penny from the year-ago comparable figure.
The downside in the bottom-line results can primarily be attributed to a double-digit increase in operating expenses, a result of management’s decision to increase investments in research and development (R&D) and international sales and marketing (S&M).
Total Revenue
In the fiscal first quarter, Abaxis delivered revenues of $57.7 million, reflecting an 8.7% year-over-year increase. The top line however missed the Zacks Consensus Estimate of $59 million.
Notably, the mid-single-digit growth witnessed in its medical market segment and the double-digit growth in veterinary market segment collectively drove the high-single digit growth in Abaxis’ overall revenue during the first quarter.
Foreign currency exchange rate fluctuations had almost negligible impact on Abaxis’ top line growth, as currencies reduced total revenue growth by only 0.3% in the quarter.
ABAXIS INC Price, Consensus and EPS Surprise
ABAXIS INC Price, Consensus and EPS Surprise | ABAXIS INC Quote
Segments in Detail
In the quarter, on a geographic-region basis, revenues from North America (accounting for 81.1% of total revenue) grew 11% to $46.8 million, while revenues from the international market (accounting for the rest) rose 1.3% to $10.9 million.
Abaxis operates under three main segments, namely Veterinary, Medical and Other. In the reported quarter, Veterinary sales comprised 82.7% of total sales; Medical sales contributed 15.8% while the remaining 1.5% was generated from Other.
Veterinary market revenues improved 10% year over year to $47.7 million, driven by a 6% growth in veterinary consumable revenues and 27% growth in veterinary instrument revenues. Revenues from medical market segment grew 5% year over year at $9.1 million, on account of 11% increase in medical rotor revenue while Piccolo instrument revenues dropped 19%. Revenues from the Other segment increased 6.2% to $0.87 million.
Abaxis also exhibited a strong consumable growth, up 7% year over year to $44.7 million, accounting for approximately 77.5% of the company’s total worldwide revenues in the quarter. Total Instruments sales, also, increased 5% to $11.1 million.
Operational Updates
Fiscal first-quarter gross profit rose 9% to $32 million. However, gross margin expanded only 10 basis points (bps) to 55.5%, affected by sales mix during the quarter.
R&D expenses increased 10.8% year over year to $5.2 million, while S&M expenses rose 11.7% to $11.8 million. General and administrative expenses also rose 21.5% to $4.2 million. Although the resultant operating income came in almost flat at $10.7 million for the quarter, operating margin declined 140 bps to 18.6% owing to higher operating expenses.
Financial Update
Abaxis exited fiscal first quarter with cash, cash equivalents and short and long-term investments of $153 million, up from $129.8 million in the prior quarter.
Meanwhile, Abaxis' management has approved a $30 million increase to its existing share repurchase program, making the total amount available for repurchase to $54 million at present.
Our Take
Abaxis’ first-quarter fiscal 2017 results disappointed us, with the company squarely missing the Zacks Consensus Estimate. However, on a year-over-year comparable basis a strong outcome was observed, with global sales improving across all Abaxis’ segments as well as in geographical bases. Moreover a specific rebound in Europe’s veterinary rotor units’ sales is encouraging as Abaxis had displayed a dreary performance in this space in the past two quarters.
Abaxis faced a challenging year over year comparison in the Asia Pacific region this quarter. But for the remaining quarters of fiscal 2017, management offered an improved outlook anticipating increased sales of veterinary rotors in the region. Besides, the strong cash position of Abaxis is evident from management’s decision to increase the share repurchase fund, which all the more buoys our optimism for this stock.
Zacks Rank
Abaxis currently holds a Zacks Rank #3 (Hold). Some better-ranked medical stocks are Boston Scientific Corp. (BSX - Free Report) , NuVasive, Inc. and Lonza Group Ltd (LZAGY - Free Report) . All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>